Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections

Blood

Volumn 91, Issue 4, 1998, Pages 1464-1468

  Liem, Linda M ^a   Van Lopik, Thea ^b   Van Nieuwenhuijze, Annemarie E M ^b   Van Houwelingen, Hans C ^b   Aarden, Lucien ^b   Goulmy, Els ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; ETOPOSIDE; FAS ANTIGEN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

EID: 0032519811     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.4.1464     Document Type: Article

References (47)

1. Deeg HJ, Storb R: Graft-versus-host disease: Pathophysiological and clinical aspects. Ann Rev Med 35:11, 1984
2. Beatty PG, Hansen JA, Lonton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckner CD, Clift RA, Petersen FB, Stewart PS, Stoeb RF, Sullivan KM, Tesler MC, Witherspoon RP: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 51:443, 1991
3. Walter EA, Bowden RA: Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 9:823, 1995
4. Chao NJ, Schlegel PG: Prevention and treatment of graft-versus-host disease. Ann NY Acad Sci 770:130, 1995
5. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
6. Lowin B, Hahne M, Mattman C, Tschopp J: Cytolytic T-cell toxicity is mediated through perforin and Fas lytic pathways. Nature 370:650, 1994
7. Kojima H, Shinohara N, Hanaoka S, Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai Y, Alt FW, Matsuzawa A, Yonehara S, Takayama H: Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1:357, 1994
8. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell-surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747, 1989
9. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
10. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267:10709, 1992
11. Nophar Y, Kemoer O, Brakebusch C, Aderka D, Holtmann H, Wallach D: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA fur the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269, 1990
12. Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, Squires CH, Thompson RC, Vannice JL: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331, 1990
13. Seckinger P, Zhang JH, Hauptmann B, Dayer JM: Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 87:5188, 1990
14. Loenen WA, de Vries E, Gravestein LA, Hintzen RQ, van Lier RA, Borst J: The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol 22:447, 1992
15. Engelmann H, Aderka D, Rotman D, Wallach D: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974, 1989
16. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602, 1991
17. Digel W, Porzsolt F, Schmid M, Hermann F, Lesshauer W, Brockhaus M: High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocyte leukemia. J Clin Invest 89:1690, 1992
18. Waage A, Liabakk N, Lien E, Lamvik J, Espevik T: p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 80:2577, 1992
19. van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89:4845, 1992
20. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1994
21. Goel N, Ulrich DT, St Clair EW, Fleming JA, Lynch DH, Seldin MF: Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthrit Rheum 38:1738, 1995
22. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB: Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthrit Rheum 38: 1735, 1995
23. Knipping E, Debatin K-M, Stricker K, Heilig B, Eder A, Krammer PH: Identification of soluble APO-1 in supematants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood 85:1562, 1995
24. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706, 1995
25. Liu C, Cheng J, Mountz JD: Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J310:957, 1995
26. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G: An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 156:4622, 1996
27. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G: Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156:13, 1996
28. Fujiwara M, Kariyone A: One-way occurrence of graft-versus-host disease in bone marrow chimaeras between congenic MRL mice. Immunology 53:251, 1984
29. Theophilopoulus AN, Balderas RS, Oozes Y, Aguado MT, Hang L, Morrow PR, Dixon FJ: Association of lpr gene with graft-vs.-host disease-like syndrome. J Exp Med 162:1, 1985
30. Alien RD, Marshall JD, Roths JB, Sidman CL: Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 172:1367, 1990
31. Chu JL, Ramos P, Rosendorff A, Nicolic-Zugic J, Lacy E, Matsuzawa A, Elkon KB: Massive upregulation of the Fas ligand in lpr and gld mice: Implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 181:393, 1995
32. Levy RB, Baker M, Podack ER: Perforin-deficient T cells can induce graft-versus-host disease after transplantation of MHC-matched or MHC disparate allogeneic bone marrow. Ann NY Acad Sci 770:366, 1995
33. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
34. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB: A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157:5387, 1996
35. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lemer KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295, 1974
36. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11:294, 1995
37. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GvHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
38. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364:806, 1993
39. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
40. Russell JH, Wang R: Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur J Immunol 23:2379, 1993
41. Russell JH, Rush B, Weaver C, Wang R: Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 90:4409, 1993
42. Gillette-Ferguson I, Sidman CL: A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmune lpr and gld mice. Eur J Immunol 24:1181, 1994
43. Vignaux F, Golstein P: Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: A regulatory pathway? Eur J Immunol 24:923, 1994
44. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438, 1995
45. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441, 1995
46. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444, 1995
47. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71, 1995